NCT02044874

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

A 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Phase 2 Dose Selection Study of Lorcaserin Hydrochloride, an Oral 5-HT2C Receptor Agonist for Smoking Cessation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 603 (actual)
• Sponsor: Arena Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.

Conditions

• Smoking Cessation

Interventions

Type	Name	Description
DRUG	APD356-lorcaserin hydrochloride
DRUG	Placebo

Timeline

• Start date: 2014-03-01
• Primary completion: 2014-11-01
• Completion: 2014-11-01
• First posted: 2014-01-24
• Last updated: 2019-04-16
• Results posted: 2019-04-16

Locations

31 sites across 1 country: United States